India Tarceva India Tarceva purchasing agent 13501239552 Tarceva purchasing agent

Tarceva is a highly efficient, highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor produced by India Co., Ltd. It is an option for patients with progressive and metastatic disease after chemotherapy failure. of new therapeutic drugs. It is an oral tablet that only needs to be taken once a day. It is safe, non-toxic, well tolerated, and has good effects on a variety of solid tumors, especially advanced non-small cell lung cancer. Tarceva has passed the certification licenses of the United States and the European Union in January and September. Tarceva can block a receptor located on the surface of tumor cells that can induce cell growth and division, thereby slowing down and preventing tumor growth and significantly improving patient survival.
Tarceva is a molecular targeted therapy drug that can specifically target tumor cells during the anti-cancer process. By inhibiting the activity of a specific enzyme on epidermal growth factor in human cells, Tarceva It can achieve the anti-tumor effect by promoting the formation and growth of tumor cells or promoting the apoptosis of tumor cells. It is currently the only latest national anti-cancer product proven to have reliable efficacy in advanced non-small cell lung cancer, and can effectively improve the survival rate of patients with tumors. , clinical efficacy is significant.
Summary of the clinical efficacy of Tarceva: A large number of clinical experiments have shown that Tarceva can significantly improve the prognosis of patients compared with placebo, with an improvement rate of up to .%, extending the survival period and improving the quality of life of patients.